Awakening guardian angels: drugging the p53 pathway

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683

p53, guardian of the genome

Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113

hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase

Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,690

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473

Systematic identification of genomic markers of drug sensitivity in cancer cells

Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456

Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies

Pistritto, G., Trisciuoglio, D., Ceci, C., Garufi, A., & D’Orazi, G. (2016) · Aging · doi:10.18632/aging.100934 · Cited by 1,721

MDM2, MDMX and p53 in oncogenesis and cancer therapy

Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279

Senescence in tumours: evidence from mice and humans

Collado, M., & Serrano, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2772 · Cited by 1,124

Senescence and aging: the critical roles of p53

Rufini, A., Tucci, P., Celardo, I., & Melino, G. (2013) · Oncogene · doi:10.1038/onc.2012.640 · Cited by 798

Drugging the p53 pathway: understanding the route to clinical efficacy

Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 742

Radiation-induced cell death mechanisms

Eriksson, D., & Stigbrand, T. I. (2010) · Tumor Biology · doi:10.1007/s13277-010-0042-8 · Cited by 704

The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches

Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 675

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595

On the binding affinity of macromolecular interactions: daring to ask why proteins interact

Kastritis, P. L., & Bonvin, A. M. J. J. (2012) · Journal of The Royal Society Interface · doi:10.1098/rsif.2012.0835 · Cited by 547

Oncogenes and Tumor Suppressor GenesPreprint

Lee, E. Y., & Muller, W. J. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003236 · Cited by 575

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462

Advances in Targeting ‘Undruggable’ transcription Factors With Small Molecules

Henley, M. J., & Koehler, A. N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00199-0 · Cited by 409

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406

The role of mutant p53 in human cancer

Goh, A. M., Coffill, C. R., & Lane, D. P. (2010) · The Journal of Pathology · doi:10.1002/path.2784 · Cited by 408

Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development

Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000657 · Cited by 395

Translating p53 into the clinic

Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381

The molecular pathogenesis of head and neck squamous cell carcinoma

Rothenberg, S. M., & Ellisen, L. W. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59889 · Cited by 372

Protein Folding and Mechanisms of Proteostasis

Díaz‐Villanueva, J. F., Díaz-Molina, R. J., & García‐González, V. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160817193 · Cited by 354

p53 Acetylation: Regulation and Consequences

Reed, S. M., & Quelle, D. E. (2014) · Cancers · doi:10.3390/cancers7010030 · Cited by 344

Tumor-Suppressor Functions of the TP53 PathwayPreprint

Aubrey, B. J., Strasser, A., & Kelly, G. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026062 · Cited by 352

MDM4 is a key therapeutic target in cutaneous melanoma

Gembarska, A., Luciani, F., Fedele, C., Russell, E. A., Dewaele, M., Villar, S., Zwolinska, A., Haupt, S., de Lange, J., Yip, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2863 · Cited by 327

Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma

Elmusrati, A., Wang, J. Q., & Wang, C. (2021) · International Journal of Oral Science · doi:10.1038/s41368-021-00131-7 · Cited by 335

Dysregulation of microRNAs in cancer: Playing with fire

Melo, S. A., & Esteller, M. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.08.009 · Cited by 324

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression

Li, Y., Yang, J., Aguilar, A., McEachern, D., Przybranowski, S., Liu, L., Yang, C.-Y., Wang, M., Han, X., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00909 · Cited by 312

Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges

Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026245 · Cited by 300

MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models

Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2807 · Cited by 283

Hydrocarbon Stapled Peptides as Modulators of Biological Function

Cromm, P. M., Spiegel, J., & Grossmann, T. N. (2015) · ACS Chemical Biology · doi:10.1021/cb501020r · Cited by 294

Regulation of the p53 response and its relationship to cancer

Meek, D. W. (2015) · Biochemical Journal · doi:10.1042/bj20150517 · Cited by 311

Pathological Unfoldomics of Uncontrolled Chaos: Intrinsically Disordered Proteins and Human Diseases

Uversky, V. N., Davé, V., Iakoucheva, L. M., Malaney, P., Metallo, S. J., Pathak, R. R., & Joerger, A. C. (2014) · Chemical Reviews · doi:10.1021/cr400713r · Cited by 288

A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53

Bernal, F., Wade, M. R., Godes, M., Davis, T. N., Whitehead, D. G., Kung, A. L., Wahl, G. M., & Walensky, L. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.024 · Cited by 288

The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway.

Korotchkina, L. G., Leontieva, O. V., Bukreeva, E. I., Demidenko, Z. N., Gudkov, A. V., & Blagosklonny, M. V. (2010) · Aging · doi:10.18632/aging.100160 · Cited by 278

Paradoxical suppression of cellular senescence by p53

Demidenko, Z. N., Korotchkina, L. G., Gudkov, A. V., & Blagosklonny, M. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002298107 · Cited by 273

The complexity of TRIM28 contribution to cancer

Czerwińska, P., Mazurek, S., & Wiznerowicz, M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0374-4 · Cited by 285

A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis.

Kracikova, M., Akiri, G., George, A., Sachidanandam, R., & Aaronson, S. A. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2012.155 · Cited by 261

MicroRNA regulation of core apoptosis pathways in cancer

Lima, R. T., Busacca, S., Almeida, G. M., Gaudino, G., Fennell, D. A., & Vasconcelos, M. H. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.11.005 · Cited by 265

Structure of the Stapled p53 Peptide Bound to Mdm2

Baek, S., Kutchukian, P. S., Verdine, G. L., Huber, R., Holak, T. A., Lee, K. W., & Popowicz, G. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2090367 · Cited by 259

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

Tisato, V., Voltan, R., Gonelli, A., Secchiero, P., & Zauli, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0500-5 · Cited by 259

Oncogene-induced senescence: the bright and dark side of the response

Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.07.013 · Cited by 257

Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53

Wilcken, R., Liu, X., Zimmermann, M. O., Rutherford, T. J., Fersht, A. R., Joerger, A. C., & Boeckler, F. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja301056a · Cited by 243

Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics

Πέττα, Ι., Lievens, S., Libert, C., Tavernier, J. H., & Bosscher, K. D. (2015) · Molecular Therapy · doi:10.1038/mt.2015.214 · Cited by 248

Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms

Allen, M. A., Andrysík, Z., Dengler, V. L., Mellert, H. S., Guarnieri, A. L., Freeman, J. A., Sullivan, K. D., Galbraith, M. D., Luo, X., Kraus, W. L., et al. (2014) · eLife · doi:10.7554/elife.02200 · Cited by 241

Small molecule induced reactivation of mutant p53 in cancer cells

Liu, X., Wilcken, R., Joerger, A. C., Chuckowree, I., Amin, J., Spencer, J., & Fersht, A. R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt305 · Cited by 246

ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis

Shi, Y., Nikulenkov, F., Zawacka‐Pankau, J., Li, H., Gabdoulline, R. R., Xu, J., Eriksson, S. E., Hedström, E., Issaeva, N., Kel, A. E., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2013.186 · Cited by 236

In Vivo Activation of the p53 Tumor Suppressor Pathway by an Engineered Cyclotide

Ji, Y., Majumder, S., Millard, M., Borra, R., Bi, T., Elnagar, A. Y., Neamati, N., Shekhtman, A. G., & Camarero, J. A. (2013) · Journal of the American Chemical Society · doi:10.1021/ja405108p · Cited by 237

Staying alive

Valcourt, J. R., Lemons, J. M. S., Haley, E. M., Kojima, M. L., Demuren, O. O., & Coller, H. A. (2012) · Cell Cycle · doi:10.4161/cc.19879 · Cited by 240

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

Graves, B., Thompson, T., Xia, M., Janson, C., Lukacs, C., Deo, D., Di Lello, P., Fry, D., Garvie, C., Huang, K.-S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203789109 · Cited by 230

D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms

Liu, M., Li, C., Pazgier, M., Li, C., Mao, Y., Lv, Y., Gu, B., Wei, G., Yuan, W., Zhan, C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008930107 · Cited by 236

Antitumoral activity of quinoxaline derivatives: A systematic review

Montana, M., Mathias, F., Terme, T., & Vanelle, P. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.059 · Cited by 228

Drugging Undruggable Molecular Cancer Targets

Lazo, J. S., & Sharlow, E. R. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103440 · Cited by 234

The Consequences of Chromosome Segregation Errors in Mitosis and Meiosis

Potapova, T., & Gorbsky, G. J. (2017) · Biology · doi:10.3390/biology6010012 · Cited by 238

Functionalised staple linkages for modulating the cellular activity of stapled peptides

Lau, Y. H., de Andrade, P., Quah, S. T., Rossmann, M., Laraia, L., Sköld, N., Sum, T. J., Rowling, P. J. E., Joseph, T. L., Verma, C. S., et al. (2014) · Chemical Science · doi:10.1039/c4sc00045e · Cited by 218

An insight into the therapeutic potential of quinazoline derivatives as anticancer agents

Shagufta, S., & Ahmad, I. (2017) · MedChemComm · doi:10.1039/c7md00097a · Cited by 213

Stapled Peptides with Improved Potency and Specificity That Activate p53

Brown, C. J., Quah, S. T., Jong, J., Goh, A. M., Chiam, P. C., Khoo, K. H., Choong, M. L., Lee, M. A., Yurlova, L., Zolghadr, K., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb3005148 · Cited by 206

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

Kojima, K., Kornblau, S. M., Ruvolo, V. R., Dilip, A., Duvvuri, S. R., Davis, R. E., Zhang, M., Wang, Z., Coombes, K. R., Zhang, N., et al. (2013) · Blood · doi:10.1182/blood-2012-08-447581 · Cited by 210

Stress-Responsive Sestrins Link p53 with Redox Regulation and Mammalian Target of Rapamycin Signaling

Budanov, A. V. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3530 · Cited by 208

Antimitotic drugs in the treatment of cancer

van Vuuren, R. J., Visagie, M. H., Mercier, A. E., & Joubert, A. M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2903-8 · Cited by 210

Protein-protein interaction networks: probing disease mechanisms using model systems

Kuzmanov, U., & Emili, A. (2013) · Genome Medicine · doi:10.1186/gm441 · Cited by 197

Targeting the ubiquitin–proteasome system for cancer therapy

Shen, M., Schmitt, S. M., Buac, D., & Dou, Q. P. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.815728 · Cited by 204

Endogenous Retroviruses and the Development of Cancer

Kassiotis, G. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302972 · Cited by 202

Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation

Huang, S., Li, C., Armstrong, E. A., Peet, C. R., Saker, J., Amler, L. C., Sliwkowski, M. X., & Harari, P. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1611 · Cited by 190

Recent Advances in p53 Research and Cancer Treatment

Suzuki, K., & Matsubara, H. (2011) · BioMed Research International · doi:10.1155/2011/978312 · Cited by 191

The TP53 website: An integrative resource centre for the TP53 mutation database and TP53 mutant analysis

Leroy, B., Fournier, J. L., Ishioka, C., Monti, P., Inga, A., Fronza, G., & Soussi, T. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1033 · Cited by 185

Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation

Topatana, W., Juengpanich, S., Li, S., Cao, J., Hu, J., Lee, J., Suliyanto, K., Ma, D., Zhang, B., Chen, M., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00956-5 · Cited by 193

Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review

Nishida, N., & Goel, A. (2011) · Current Genomics · doi:10.2174/138920211795564359 · Cited by 183

Local activation of p53 in the tumor microenvironment overcomes immune suppression and enhances antitumor immunity

Guo, G., Yu, M., Xiao, W., Celis, E., & Cui, Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2832 · Cited by 168

Aneuploidy and chromosomal instability: a vicious cycle driving cellular evolution and cancer genome chaos

Potapova, T., Zhu, J., & Li, R. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9436-6 · Cited by 170

p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewalPreprint

Zhao, Z., Zuber, J. A., Díaz-Flores, E., Lintault, L., Kogan, S. C., Shannon, K., & Lowe, S. W. (2010) · Genes & Development · doi:10.1101/gad.1940710 · Cited by 175

The Structure‐Based Design of Mdm2/Mdmx–p53 Inhibitors Gets Serious

Popowicz, G. M., Dömling, A. S. S., & Holak, T. A. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201003863 · Cited by 170

The role of DNA damage responses in p53 biology

Speidel, D. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1459-z · Cited by 172

Reactive Oxygen Species Induced p53 Activation: DNA Damage, Redox Signaling, or Both?

Shi, T., & Dansen, T. B. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8074 · Cited by 173

Mage-A Cancer/Testis Antigens Inhibit p53 Function by Blocking Its Interaction with Chromatin

Marcar, L., MacLaine, N. J., Hupp, T. R., & Meek, D. W. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1341 · Cited by 163

Current strategies to target p53 in cancer

Chen, F., Wang, W., & El‐Deiry, W. S. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.031 · Cited by 158

Small Molecule Structure Correctors Abolish Detrimental Effects of Apolipoprotein E4 in Cultured Neurons

Chen, H.-K., Liu, Z., Meyer-Franke, A., Brodbeck, J., Miranda, R. D., McGuire, J. G., Pleiss, M. A., Ji, Z.-S., Balestra, M. E., Walker, D. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276162 · Cited by 163

Silver-Based Nanoparticles Induce Apoptosis in Human Colon Cancer Cells Mediated Through P53

Satapathy, S. R., Mohapatra, P., Preet, R., Das, D., Sarkar, B., Choudhuri, T., Wyatt, M. D., & Kundu, C. N. (2013) · Nanomedicine · doi:10.2217/nnm.12.176 · Cited by 150

Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers

Ehsanian, R., Waes, C. V., & Feller, S. M. (2011) · Cell Communication and Signaling · doi:10.1186/1478-811x-9-13 · Cited by 150

Protein Regulation in Signal TransductionPreprint

Lee, M. J., & Yaffe, M. B. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005918 · Cited by 145

Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists

Shen, H., & Maki, C. G. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222603 · Cited by 148

Systematic Mutational Analysis of Peptide Inhibition of the p53–MDM2/MDMX Interactions

Li, C. V., Pazgier, M., Li, C., Yuan, W., Liu, M., Wei, G., Lu, W., & Lu, W. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.03.005 · Cited by 149

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine

Fiorini, C., Cordani, M., Padroni, C., Blandino, G., Agostino, S. D., & Donadelli, M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.10.003 · Cited by 151

The DNA damage response and immune signaling alliance: Is it good or bad? Nature decides when and where

Pateras, I. S., Havaki, S., Nikitopoulou, X., Vougas, K. N., Townsend, P. A., Panayiotidis, M. I., Georgakilas, A. G., & Gorgoulis, V. G. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.011 · Cited by 147

Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells

Puca, R., Nardinocchi, L., Givol, D., & D’Orazi, G. (2010) · Oncogene · doi:10.1038/onc.2010.183 · Cited by 141

Pharmacological reactivation of mutant p53: from protein structure to the cancer patient

Wiman, K. G. (2010) · Oncogene · doi:10.1038/onc.2010.188 · Cited by 148

p53 Isoforms and Their Implications in Cancer

Vieler, M., & Sanyal, S. (2018) · Cancers · doi:10.3390/cancers10090288 · Cited by 153

Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture

Apontes, P., Leontieva, O. V., Demidenko, Z. N., Li, F., & Blagosklonny, M. V. (2011) · Oncotarget · doi:10.18632/oncotarget.248 · Cited by 139

“Recycling” Classical Drugs for Malaria

Teixeira, C. A. S., Vale, N., Pérez, B. C., Gomes, A., Gomes, J. R. B., & Gomes, P. A. C. (2014) · Chemical Reviews · doi:10.1021/cr500123g · Cited by 139

Cellular senescence and cancer chemotherapy resistance

Gordon, R. R., & Nelson, P. S. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.002 · Cited by 138

Wild-type p53 controls cell motility and invasion by dual regulation of MET expression

Hwang, C., Matoso, A., Corney, D. C., Flesken‐Nikitin, A., Körner, S., Wang, W., Boccaccio, C., Thorgeirsson, S. S., Comoglio, P. M., Hermeking, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017536108 · Cited by 137

Nucleotide Biosynthetic Enzyme GMP Synthase Is a TRIM21-Controlled Relay of p53 Stabilization

Reddy, B. A., van der Knaap, J. A., Bot, A. G. M., Mohd-Sarip, A., Dekkers, D. H. W., Timmermans, M. A. M., Martens, J. W. M., Demmers, J., & Verrijzer, C. P. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.12.017 · Cited by 133

Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer

Galluzzi, L., Vitale, I., Senovilla, L., Olaussen, K. A., Pinna, G., Eisenberg, T., Goubar, A., Martins, I., Michels, J., Kratassiouk, G., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.06.017 · Cited by 137

Voxelwise gene-wide association study (vGeneWAS): Multivariate gene-based association testing in 731 elderly subjects

Hibar, D. P., Stein, J. L., Omid Kohannim, A., Jahanshad, N., Saykin, A. J., Shen, L., Kim, S., Pankratz, N., Foroud, T., Huentelman, M. J., et al. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.03.077 · Cited by 132

Schiff Bases and their Metal Complexes as Potential Anticancer Candidates: A Review of Recent Works

Tadele, K. T., & Tsega, T. W. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666190227171716 · Cited by 130

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

Bonnefoi, H. R., Piccart, M. J., Bogaerts, J., Mauriac, L., Fumoleau, P., Brain, E. G. C., Petit, T., Rouanet, P., Jassem, J., Blot, E., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70094-8 · Cited by 131

Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications

Perri, F., Pacelli, R., Scarpati, G. D. V., Cella, L., Giuliano, M., Caponigro, F., & Pepe, S. (2014) · Head & Neck · doi:10.1002/hed.23837 · Cited by 128

Double Strain‐Promoted Macrocyclization for the Rapid Selection of Cell‐Active Stapled Peptides

Lau, Y. H., Wu, Y., Rossmann, M., Tan, B. X., de Andrade, P., Tan, Y. S., Verma, C. S., McKenzie, G. J., Venkitaraman, A. R., Hyvönen, M., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201508416 · Cited by 128

Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia

Stilgenbauer, S., & Zenz, T. (2010) · Hematology · doi:10.1182/asheducation-2010.1.481 · Cited by 125

Small-Molecule Structure Correctors Target Abnormal Protein Structure and Function: Structure Corrector Rescue of Apolipoprotein E4–Associated Neuropathology: Miniperspective

Mahley, R. W., & Huang, Y. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3008618 · Cited by 132

Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition

Wilcken, R., Wang, G., Boeckler, F. M., & Fersht, A. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211550109 · Cited by 120

The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy

Woods, S. J., Hannan, K. M., Pearson, R. B., & Hannan, R. D. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.10.007 · Cited by 120

Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis

Ito, M., Barys, L., O'Reilly, T., Young, S., Gorbatcheva, B., Monahan, J., Zumstein-Mecker, S., Choong, P. F., Dickinson, I., Crowe, P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2050 · Cited by 115

Drugging the p53 pathway: understanding the route to clinical efficacy

Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 742

Small molecule compounds targeting the p53 pathway: are we finally making progress?

Yu, X., Narayanan, S., Vázquez, A., & Carpizo, D. R. (2014) · APOPTOSIS · doi:10.1007/s10495-014-0990-3 · Cited by 68

ORIGINAL PAPER Small molecule compounds targeting the p53 pathway: are we finally making progress?

Yu, X., Narayanan, S., Vazquez, A., & Carpizo, D. R. (2014)

The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches

Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 675

Translational approaches targeting the p53 pathway for anti‐cancer therapy

Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77